rethinkTHC Search
Menu
Study breakdown

Cannabis Shows Promise for Inflammatory Bowel Disease But Needs Larger Clinical Trials

Narrative ReviewPreliminary evidence
The takeaway

Cannabis interacts with CB1 and CB2 receptors throughout the gut and immune system to reduce inflammation, motility, and secretions, showing symptomatic benefits in small IBD studies, but large controlled trials are still lacking.

IBD patients exploring cannabis, gastroenterologists, and medical cannabis researchers.

Cannabinoids reduce gut motility, secretions, and inflammatory edema through CB1 and CB2 receptors

What the researchers found

Cannabinoids act on CB1 and CB2 receptors in the enteric nervous system, GI epithelial cells, and immune cells, reducing gut motility, secretions, and inflammatory edema. Small observational studies and placebo-controlled trials have shown symptomatic improvement, but sample sizes have been too small for firm efficacy and safety conclusions.

Why it matters

IBD affects millions of people globally, and current treatments often have significant side effects or lose effectiveness over time. Cannabis represents a potentially well-tolerated complementary approach, but the evidence gap is significant.

The numbers in context

CB1 and CB2 receptors expressed in brain, enteric nervous system, GI epithelial cells, and immune cells; effects: decreased gut motility, reduced secretions, reduced inflammatory edema

How the study worked

Narrative review of observational and placebo-controlled trials examining cannabis and cannabinoids in Crohn's disease and ulcerative colitis, alongside preclinical mechanism data.

What this study cannot tell us

Narrative review. Existing clinical trials have small sample sizes. No standardized cannabinoid compositions across studies. Long-term safety data lacking. Psychotropic side effects of THC limit some applications.

How to read the evidence

Narrative review of small clinical studies. Biological rationale is strong but clinical evidence remains limited.

When this study was published

Published in 2024.

The bigger picture

The endocannabinoid system's extensive presence in the gut provides a strong biological rationale for cannabinoid therapy in IBD. The challenge is moving from preclinical promise to clinical evidence through adequately powered trials.

Questions still open

  • Would standardized cannabis preparations with specific cannabinoid ratios be more effective for IBD?
  • Could cannabis derivatives without psychoactive effects provide the anti-inflammatory benefits needed?

Common questions

Can cannabis help with IBD?
Small studies show symptomatic improvement, and the biological mechanism is well-understood. But evidence from large controlled trials is still lacking.
How does cannabis work in the gut?
Cannabis compounds interact with CB1 and CB2 receptors in the gut to reduce inflammation, slow motility, and decrease secretions.

Read the original research

The Potential of Cannabis in Managing Inflammatory Bowel Disease and Its Future Perspective.

Cureus, 16(10), e71068

Citation

Rauf, Arsalan; Nisar, Mudassar; Shaeel, Muhammad; Athar, Ali; Rehman, Muhammad Mujtaba Ur; Faheem, Filzah. (2024). The Potential of Cannabis in Managing Inflammatory Bowel Disease and Its Future Perspective.. Cureus, 16(10), e71068. https://doi.org/10.7759/cureus.71068

Explore the wider topic